Konruns Pharmaceutical
Innovative drug development for perioperative and oncology markets.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 7 % | 6 % | (10 %) | 13 % | 30 % | 38 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 28 % | 21 % | 20 % | 19 % | 23 % | 22 % | 20 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 18 % | 12 % | 16 % | 5 % | 16 % | 15 % | 14 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 13 % | 10 % | 10 % | 7 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Beijing Konruns Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company focused on the research, development, manufacturing, and sale of innovative drugs. Founded in 2003 and headquartered in Beijing, China, the company has established a comprehensive industry presence, integrating R&D, production, and marketing. Konruns Pharmaceutical was listed on the Shanghai Stock Exchange in August 2018 under the stock code 603590.
The company's core mission is "using life science to care for human health," with a strategic focus on developing novel drugs that address unmet clinical needs. Its primary therapeutic areas include hemostasis and perioperative care, oncology/immunity, and bone metabolism. A key product in its portfolio is "Sulin®," a national Class 1 new drug. Sulin is a hemagglutinin agent used to control bleeding during surgical procedures and from trauma. In 2020, Konruns expanded its product line by acquiring the salmon calcitonin injection and nasal spray from Novartis, adding to its offerings in bone metabolism and providing new avenues for profit growth. The company also has a pipeline of new drugs under development, including KC1036.
Konruns Pharmaceutical operates primarily in the domestic Chinese market, serving a growing network of hospitals. Its business model revolves around the direct manufacturing and sales of its proprietary and acquired pharmaceutical products. The company has received numerous honors, including being named a National Intellectual Property Demonstration Enterprise and a Beijing G20 Leading Enterprise, reflecting its commitment to innovation and quality in the pharmaceutical sector.
Keywords: pharmaceutical manufacturing, innovative drugs, oncology, hemostasis, perioperative care, drug development, Sulin, salmon calcitonin, KC1036, bone metabolism, surgical bleeding, blood-related diseases, Chinese pharmaceutical market, publicly traded, Shanghai Stock Exchange, life sciences, clinical needs
